Genomic Valley Biotech Ltd vs Walchand Peoplefirst Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Mar 23, 2026

Key Highlights

The Latest Trading Price of Genomic Valley Biotech Ltd is ₹ 28.56 as of 20 Mar 15:30 . The P/E Ratio of Genomic Valley Biotech Ltd changed from 694.2 on March 2024 to 50.1 on March 2025 . This represents a CAGR of -73.14% over 2 yearsThe P/E Ratio of Walchand Peoplefirst Ltd changed from 20.9 on March 2022 to 19 on March 2025 . This represents a CAGR of -2.35% over 4 years The Market Cap of Genomic Valley Biotech Ltd changed from ₹ 10.6 crore on March 2024 to ₹ 17.9 crore on March 2025 . This represents a CAGR of 29.95% over 2 yearsThe Market Cap of Walchand Peoplefirst Ltd changed from ₹ 17.25 crore on March 2021 to ₹ 34.18 crore on March 2025 . This represents a CAGR of 14.66% over 5 years The revenue of Genomic Valley Biotech Ltd for the Dec '25 is ₹ 0.05 crore as compare to the Sep '25 revenue of ₹ 0.09 crore. This represent the decline of -44.44% The revenue of Walchand Peoplefirst Ltd for the Dec '25 is ₹ 10.04 crore as compare to the Sep '25 revenue of ₹ 10.07 crore. This represent the decline of -0.3% The ebitda of Genomic Valley Biotech Ltd for the Dec '25 is ₹ 0.01 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the growth of 9.2233718E16% The ebitda of Walchand Peoplefirst Ltd for the Dec '25 is ₹ 1.89 crore as compare to the Sep '25 ebitda of ₹ 1.72 crore. This represent the growth of 9.88% The net profit of Genomic Valley Biotech Ltd changed from ₹ 0.13 crore to ₹ 0.01 crore over 7 quarters. This represents a CAGR of -76.91% The net profit of Walchand Peoplefirst Ltd changed from ₹ -0.22 crore to ₹ 1.36 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Genomic Valley Biotech Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Walchand Peoplefirst Ltd changed from 19.59 % on March 2022 to 16.11 % on March 2025 . This represents a CAGR of -4.77% over 4 years .

About Genomic Valley Biotech Ltd

Incorporated in May 1994, Genomic Valley Biotech Limited is formed with the objective of conducting research in the field of Biotechnology (Plant & Animal) and also to undertake commercial production of Plant Tissue Cultured Plants of different species to feed the genetically improved plant market nationally as well as internationally.
The Company is extensively involved in commercial greenhouse / poly house cultivation of crops.
Presently, it is engaged in high-tech cultivation through environmental controlled Poly Houses,NFT & DFT etc,manufacturing of Tissue Cultured Improved variety of plants and organic farming using Bio-Fertilizer.
Also it is involved in commercial Horticulture activities with Aloe vera, Tomato, Bitter Gourd, Bottle Gourd, Brinjal, Broccoli, Cabbage, Capsicum, Carrot, Cauliflower, Cucumber, Green Chillies, Onion, Radish, Ridge/Sponge Gourd, Leafy Vegetables, Pumpkin, Banana, Guava, Papaya, and Strawberry.

About Walchand Peoplefirst Ltd

Formerly known as Premier Construction, Walchand Hindusthan (WHL) was incorporated in 1920 by the erstwhile Walchand Hirachand group.
The company is engaged in construction contracts and leasing.
WHL controlled the family's stakes in each of the companies of the Walchand group.
The family's stake in turn was determined through a private company Walchand and Company which held a majority stake in WHL. While Vinod, Chakor and Arvind Doshi together held about 45% of Walchand and Company, the Bahubai faction together owned 55% of Walchand and Company.
With the split in the Walchand group, the construction house, owned by the company was vacated by the Doshi companies. Hindustan Construction (HCC) increased its share in the company to 51% by way of a preferential issue at the then prevailing market price of Rs 330.

FAQs for the comparison of Genomic Valley Biotech Ltd and Walchand Peoplefirst Ltd

Which company has a larger market capitalization, Genomic Valley Biotech Ltd or Walchand Peoplefirst Ltd?

Market cap of Genomic Valley Biotech Ltd is 8 Cr while Market cap of Walchand Peoplefirst Ltd is 28 Cr

What are the key factors driving the stock performance of Genomic Valley Biotech Ltd and Walchand Peoplefirst Ltd?

The stock performance of Genomic Valley Biotech Ltd and Walchand Peoplefirst Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Genomic Valley Biotech Ltd and Walchand Peoplefirst Ltd?

As of March 23, 2026, the Genomic Valley Biotech Ltd stock price is INR ₹28.56. On the other hand, Walchand Peoplefirst Ltd stock price is INR ₹96.8.

How do dividend payouts of Genomic Valley Biotech Ltd and Walchand Peoplefirst Ltd compare?

To compare the dividend payouts of Genomic Valley Biotech Ltd and Walchand Peoplefirst Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.